[HTML][HTML] COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …
addition to those faced by the general population, including concerns about higher risks of …
The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta …
Aims To estimate the association of smoking status with rates of (i) infection,(ii)
hospitalization,(iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease …
hospitalization,(iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease …
American College of Rheumatology guidance for COVID‐19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2
JR Curtis, SR Johnson, DD Anthony… - Arthritis & …, 2021 - Wiley Online Library
Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …
[HTML][HTML] Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global …
JA Sparks, ZS Wallace, AM Seet… - Annals of the …, 2021 - ard.bmj.com
Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …
[HTML][HTML] Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in …
Background The risk of severe COVID-19 outcomes in people with immune-mediated
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform …
FPB Kroon, A Najm, A Alunno, JW Schoones… - Annals of the …, 2022 - ard.bmj.com
Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
Risk of COVID‐19 in rheumatoid arthritis: a National Veterans Affairs matched cohort study in at‐risk individuals
Objective Rheumatoid arthritis (RA) and its treatments are associated with an increased risk
of infection, but it remains unclear whether these factors have an impact on the risk or …
of infection, but it remains unclear whether these factors have an impact on the risk or …
Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States
R Raiker, C DeYoung, H Pakhchanian, S Ahmed… - Seminars in arthritis and …, 2021 - Elsevier
Objectives To investigate outcomes of Coronavirus Disease-2019 (COVID-19) in patients
with rheumatoid arthritis (RA) as compared to the general population. Additionally, outcomes …
with rheumatoid arthritis (RA) as compared to the general population. Additionally, outcomes …
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease
R Fernandez-Ruiz, JL Paredes, TB Niewold - Translational Research, 2021 - Elsevier
As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
MF Ugarte-Gil, GS Alarcón, Z Izadi… - Annals of the …, 2022 - ard.bmj.com
Aim To determine characteristics associated with more severe outcomes in a global registry
of people with systemic lupus erythematosus (SLE) and COVID-19. Methods People with …
of people with systemic lupus erythematosus (SLE) and COVID-19. Methods People with …